1

104

104 10

50.4 26

104 1-11 6,010

1,191

(113 )104 20 15

104 1-9

35 104 56

4

249

2

104 9

134 71

104 1.4

2

104

6 6,766

92

65

104 1 7 72

104 22 10

104 6 3

9

97 2.3% 104 12 35%104

220 27

2,476 104 11

104 1 11 12.4

96 104 1

9 4,753 9,407

95

3

102 1 105 1

2,302

104 11 324

263

36.9

104 13.9 4

102

103 20%

15% 104 1

8,853

(103 3 104 3 )

78.28

13

4

104 5.7

6,855 7 7

12 11

160 145

3,885

104 10 33 6

23.9% 27.7% 9

104

506.34 1.1 4.8

104 12 7

105 1

210 92 40

194

5

48 (104 7%105

4%106 0%)

104

88

104 12 30 105

6 30

910

7

4

24

(0800-788-995)104 7

12,152464

: 104 2 4 12 16

:104 9 18

104

12 31 30

6

104 11 17 12 2

104 7 1 105 3 3

1,266 84 104

1012907,10898.76

H5N1H7N9 A

A 104 1 1 105 2

25 A 85

105 3 3

104 105 2 25

43,687 229

74

104

2

10 33%

7

103

48.4 103

(WEF) 69 3

104 11

104 12 14

WEF2015

105 1 10 Zika virus

20035

105 2 2

24

Alert

0206

2 6

313 ()(

)() 220

0206 23

8

23

2 6

REMOC

2 6

REMOC ()

2 14

192

(

) 105 2 6

2 14

391 661

105 2 6

2 15 561 34 105

3 1 11 14 ( 3

11 )

105 3

15 1

9

3 105 6 30

105

() 9

Tw-DRGs

Tw-DRGs

DRG

WTO

(ECMO)

( 19 ( 6,000

105 1 1

)

10

106-109

4

(WHA)

(APEC)()

0206

/

1

9 1

0206

()

1. 101

2

20 2,500

5,000104 50 4,509 1,349

25 5,722

2.

3,000 104

2

1 4,074 6,010 7,777

3 7,691

3.

104 27 7 1,191

4.

104 6

3,190 1,452

5.

104

122 5,004 3,471

1,384 352

2,604(1

1.5) 1,662

6.(CRC)

(1) 103 11

20

103 11 20

105 1 25

(2) 103 1

CRC

CRC

(3) CRC 9

104 11 20

3

104 11 18

7/13/18

(4)

105 11

106 11

()

1.

(1)

104 12 868

(2)

104

11,803

(3)

(4)

104

6

2.

(1) 101

104 100 144

(2)

4

101 104

92 4,258

(3) 103 12 1

104 12 2 2,933

(4) 104 12

13 2,849 7,934 7 3,350

3.

(1) 3

92 31.3% 104

45.4%

(2) 104 8

40

(3)

5,000

3,000 104 12 3 5,586

9,294 4 4,765

4.

(1)

104 2 8,730 4

1,852

(2) 6

1 18

7 6 104

5

1 3,917

(3)104

58 1,908

(4)

104 12 823

(

) 5 4,717

403

5.

104 1 9,297

4 2,012

6.104 100

626

7.104 10

11 11 765

()

1.

(

)104 12 22

2.

177 52

3. 104

1,067

5 9,869 4 6,264

6

4. 104 12

2,106

368

2 2,476

21

5.

70

104 94 6,317

6 1,641 5,251

6.

5,000 104 9 4,753

9,407

7.

7,200

3,600 104 96

3,080 12 4,490

8.()

98 104 9 3 9

9.

1,800

21 6,000 104 4

136.4

()

1.

(1) 104 2

7

4

(2)

104 2 4

(3) 104 12

23

2.

(1)

(2)

(3): 104 1 12

5 4,061

4 9,863 92.2%

(4)

104 1 12 1,500

40

(5)

3.

(1)(113)104 1

12 113 19.6

14.7

(2)

104 1 12

100 3 8,000

20

8

9,000

(3)

(4)104

1 12 40

(5)

4.

(1)104 1 12 319

189

(2)103

5.

(1)104 1 12

52

3,382

(2)

1)TAGV

104 12 TAGV

1 7,029 6

2)

3)

9

4)

5)/

/

6)

18 74

7)

6.

(1)

(2)

(3)

(4)

104

13 257 4,000

10

7. 104

4

()

1.

(1)

103 12 3

103 11 27

(2)103 12

104 2 7 11

3

2.

(1) 101 7 11 104 12

89 6,350

68 6,568

(2)

104 5 12

(3)

1957 242

(4)99

104 12 4,293

1 392

3.

11

(1) 3,500

8,200105

104 9

153 6,000 35

3,000

(2) 104 9

53 8,000 4

(3)

104 33 4,000

55 9,000

(4) 104 9

5 4,745 5

3,409

(5) 104 9

2 8,772 1

2,828

(6)

104 9 14.7

4.103( 9 )

274 11

103 10 24 104 2 25

3

12

104 9 18

8

()

1. 104 9

69

2.104 9

25 2,069 134 4,784

71 104

9 17,674 2.7

3.104 1 12 68

7,532 2,982 397 9,888

4. 97 8

18 104 1 104

12 1 4,192

2 3 1,695

5.

104 1,003 1,638.5

6.

104

32 501

104 32 1,683

13

()

1. 104 6

6,766

3,504

2.

104 9

34

3.

92 104 12

129

557 7,200

()

1. 104 6

961 101 114

1,490 64

2. 104 6

9,074

3.: 217

( 81.3) 105 5

4.

(1)

103

14

(2)

104 4 1

()

1. 40 65 3 1 55

65 1

104 1 7

133

2.

213

3.104

166

104 12 22 4,600

32

4. 104

!

1,663

5.104 1-7

65 72104

65 807 104

1-9 65

12,265

6.100

15

8 104

1,920 96%

7.

(1) 99

104 12 206

(2)102 5 WHO

104 2

8.

102 22

22104

386 94

9.

104 22 2400 10

4%100 -104

39 6

()

1.

(1)

1) 97

2.3% 104 12 35%

104 30%)

17 465

16

2)

22 62

(2) 102

1) 89

100 104

9,893

2) 368

104 12

220 27

25,055 8,531

497 25,104

3) 700 6

(11 )103 104 3

(3)104 5

1) 104 6 3

106 6104

() 9

105

104

(FB 7 6

/) 4 8

17

2

2) 5 120

2.

2 104 11 3

()

3.

104 6 4

()

1. 105 1

2,302

2. 105 1 103

467 104 1 11 417

3.104 803

2.94%

4. 102 1 1

170.6

103 104

18

105 102

56.7 103 5 7

103 82.1

104 4 104

31.8 105 4 1

()

1.Tw-DRGs

(1)104 DRG

3.96

6.5% 4 2,580

836 1.9%DRG

1.189 0.031 2.7%

DRG

(2)104 3 2.02%

0.09% 4.3% 101 104

14 3.3%

0.5% 12.6%

(3)

(4) 99 Tw-DRGs 2 401

DRGs 3-5 DRG 105 3 1

2.

19

(1) 105 15.7 ( 8.763

2.927 4.04

)

(2)104

1)46.82

2)10.29

3)1.25

4)5.97

5)B C 20.15

6)27.80

16.9

3.

()

(1) 103 1 17

50.5 103 1.002

102

(2)101 103 3.2

104 105 1.6

(3)98 103

91.65 104 20

6%

9-11%

4.

20

39

104 12 4,945

87.3%

84.6%

86.9%

5.

(1) 84

103 16

30

(2)104 4 23

()

(3)

4

3

105 2 15

()

1.

(1)104 12

324 263

(2)104 12

2,525 1.77

11.2 32.10

9,201 2,160

21

6.28

2.85

2.104 12 78.5

3.

(IDS) 50

45 104 26 30

4-6

(1)104

5.865

121 97 143

(2)

1,500 104 8

70

4.

(1)

50

(2)

100 7 1

102 1

104 13.9

4

()

1.

90 102

22

103

20% 15%103

104

2.104 70%

(

)

3.102 7 1 104 12

31 1 8,853

4.

(HTA)

104 12 HTA

18 6

()

1.

105 2 16 600

2.

(1)

75% 60%

(2) 104

12 482

418(86.7%)

23

3. 104 12

103 6 111

()

1. 104

2,171 26 104

7 20

2.104

239

105 105

3.104 18

1 32 1 105 3

1 5

1

2

4.104 11

355.7 (97 10

104 10 ) 56.22% 104

11 152

592

5.104

354

225.1 11.8

5.25%

24

6.()

(97 10 104 12 )

2.4 2.3

96.12%

()

1. 104 6 4

104 6 12 8 7

105 1 14 2 1

2. 104 7 1 105 1 15

393

44,452

3.

4.

5.

6.

13

()

1. 10 1

103 94.3% 194.9

1 98.6% 4

25

97.6%104 1 7 118.1

2. 103 11 1

2

18 104 670

1,599 90.1%

104 321,972 2

70%

3.103

104 5 7,471

1,645 6,855

1,946104 1 11

19 4,488 99%

4.104

6 45.4%

2005 2012 38% 104 12

2,135

100%

5.

104 935 104

1.083 103 1.069

6. 7 7 103

77.7% 110 1 1

97.2%104 1 7 68.1

26

7. 103 11 1 7 7

104 12

89.5%

8.101 3 15

700 104 97.8% 20 8,722

104 296 98%104

20 8,722 97.8% 795

9. 70

/(Teens 9 )

104 12

30,297

()

1.

AFHC

104 12 12 11

AFHC

2.104 19 145

259

3.

(1) 104 12 160 WHO

101

WHO-HPH Recognition Project

27

21

21 103 8 104 6

(2)104 19

131

(3) 99

104 29

104 12 174

4.104

104 1,848

1 4,287

5.

4,044

()

1. 98 132.5

103 130.2

2. 92 96 48%

97 101 54.2% 6.2%

3.18

96 17.2% 104 8.8%

4.104 1

28

1 3

(HPV)

5.104

506.3

1.1

4.8

6.

104 10

94

6 104 67 15

7.104 8

104 55

5 (

) 11

1,542

()

1. 10418

97 21.9% 17.1%7

76

97 23.7% 104 7.7%

2.104

63427 8,767 3,200

3.

29

104 9 1

4.

5.

200

104 3,435

99.4% 100%104

1-10 13 3,108 103

6.1%101 3 104 10

33 9,802 6 27.7%

23.9% 15.9% 9

4.9 378

6.0800-636363104

90,632

7.

199

27

11

8.104

4

30

283

9. 98 104

452 (70) 4,044

10.104

(1) 678 (2)

670(3) 1,334 (4)

412(5) 263

()

1. 104 2015

60 600

104 11 30 69 7,531

112 6,303.6

2.

3.

104 9 52

6

2

7,428,147

4.104

98

5.

31

()

1.

2. e

104 12 762

()

1.104 46

32

104 22,829

15,123

4,314 1,505

1,422

465

2.104 6

2,383

104

6,547 8 7,870

3.

104 1 14

32

1104 11 11

2104 11 19

3104 12 7

4

4. 105 1 210 92

40

105 1

10,240

30 33

104 2,523

732 65

1,307 395

24

5. 104 12

1,817

104 2 4

1 69

()

1.

33

104

194 36

82 76

(1) 104

102 104

4

19 18

72

(2)AED

102

(AED)

AED 104

6,000 AED CPR+AED

2.

104 19 1

8,000

()

1.104

88

34

10

2.

105

5 500

3.

103

4.

24 106

5.()

(1)

24

35

(2)

(3)

6.

(1)

105

(2)

(3)

20

(Hospitalist)

(4):

36

36

40

(5) 48

(104 7%105 4%106 0%)

()

(6)

Tw-DRGs

Tw-DRGs

(7) App

0800-030-598

7.

104 11 20

8.

(1)

104 12 361

26 334

279 2

37

6,616

(2)

7

(3) 104 12 11

104 12 30

10400151401 29

105 6 30

(4)

103 5 8

103 5 29

9.

10.

(1)

1) 104 2 9

2)

:103 8 13 104

38

20

(2)

1)

:103 20

104 20

98 103

7,522

2):101 9 21

()

100 200

900 104 1

() 96.9%

100% 96.2%

8.08%

(3)

1)

(a)

(b)

2)

104

39

3): 103 1

29 24 106

(4)

1) 102

4 26

200

2) 103 6 19 4

200 104

30

4 104 36

105 80

(5)(101 4 )

13 6,415

104 12 15 3,336

1 6,921

101

13.14% 103 11.2%

100 7.4% 103

6.1%

11.

40

103 8 5 24

104 10 19 105 1

1 104 11 3 (11 5

)

12. 95 104 5,702( 3,011

2,691)

13.104 7 3

30

()

1.

14

104 137

6,594

2.

104 40

1,386

3. 102

(OSCE)

104 25 (27

104 1,487

41

4. 102

RRC

23

104 21

2 105

23

()

1.105

182

4

11

2.:104

80 6

1104 32 2,355

IC ;

IC 302,238

()

1.

(1) 21

(2)

(3) 24 0800-788-995104

7 0,574

42

12,152 464

104 1 11 2

7,908 18 6,766

(4)103 11.8

5 10 104 1 10

2,993 103

38 1.3%

2.

(1)

96 104 1

12 14 2,416 69

9,815

(2)

104 131 (

)

(3)

104 1 12 747

95.4% 677

93.65% 70

97.1%

3.

(1)104 12

162 162

96 1 4,131

43

104 4 1,762

8

94 2,420 104

82

(2)

4.

104 1 12 1,193

103 1,907

2,297 1,837

465525() 252

5.

(1)

104 57

(2)

4

(3)104 17,253

44

(4)

5

990

6.

104 374 759

7.

(1)104

31

7

29,240

(2)

104

(3) 22

89

()

1.104

35 188

2.104

6 5 3

45

35

3. 3

()

1.

(1) 102

48

(2)(HIS):

104 64

342 105

()(

)() HIS

(3)(PACS) X

104 40

IRC 104

7,013

2. IDS

IDS

48 342

3.

(1) 910

7 105

49

(2): 1044

46

200 30

4

(3): 30

216 () 27 ()103

104 1,892

323 14 232

1,496 47

12 318

4.

(1) 24

104 1-12

273 236

(2)

()

()

104 24,466

()

1.

104 21

47

351 874 501

57%

2.

(1)100

101 104 12

184 2,824

181 35

(2) 24

104 7,551

516 13,537

(3) 101

103 20 102

104 6,481

6,887 6,804

(4) 2,027( 1,724

300 3)104

18,760

201 104 146

3. 104

295 104 10 1

104 12 78

103 6

104 11 20

104 12

18

4. 104

4 ()

48

1798 32,652

()

1. 104

4,518

2.104 8

3.

104

42

()

1.104 64

0,112 5 0,170 1,003

2.: 104 2 4 12 16

3.:

(1)

(2)

49

(3) 1919

(4)

(5)

(6)

4.:

35 4(

)

5.:

30

113

6.: 104 5 15

7.: 103 10 31

104 1 26

50

150

8.:

15.38%(104 1 1 8 5 ) 2.50%(104

8 6 12 28 ) 9 22

()

1.104 6 10

105 6 10

320

185 57.8%

2.

(1)104 7 31 7(

)2

()

12 104 7 31

19

( 6,000 )

(2)105 1 1 3 1 17

()

() 10

51

3.()

(1)104 7 31

8

104 7 31

16

(2) 31 104 12 10

104 10 15

10

( 209 ) 105 12 31

4. 7

(1)

(2)

(3)

(4)

(5)

(6)

(7)

5.:104 9 18

104 12 31 30

52

6.

(1) 104 11 20

(2) 104 12 30

6

()

1.()

2.()

3.()

4.()

5.()

() MIT

53

1. GMP (PIC/S GMP)

104 12 31 119 33

321(

223 )5 PIC/S GMP

893 PIC/S

GMP (GMP)

104 12 31 GMP/QSD

4,100 15.8%

84.2 %

2.

104

(1)

104 11 17

12 2

(2)104 7

6 7

31

9 4

11 19

12 31

(3)104 11 30

54

Peginterferon

beta-1a

104 7 13

10 2

11 2

12

3

(4)104 10 15

8

2

(5)10 16

10 30

(6)104 7 7

11

10 11 9

EstradiolEstrone

Ethinyl estradiol

3.

104 12 53

17 10 5

13

4.

55

101 104 12 247

111 4

602

310 104

8 5

375 3453

1,936

136

28

159 177

5. 104 12

610 313312 1

55 55 242

235 7

6.104 9 3

12 4 9-10

56

7-8

9-10()

10

7.104 12

7,618 22,113.8

99 1 13.9% 104

12 5%

56

8.104 25

104

104 12 759

APP

9.

104 10 13

10.

104 11 16 20

(Regulatory Science BIO Week)

11.104 11 2627

(BE)

()

1. 104 12

17,454 370 (2.1%)

2. 104 12

18,399 103 17,905

2.8%

()

1. 104 12

57

294 1,544.15

60 225.5

40 118

2.104 5 5 16

10

104 1 1 12 31 3,164

12,846

3. GMP 104 12

55 5 GMP

4.104 8 1

324

()

1.104 7 1 105 2 18

662 62

2.104 316

104 10 1 289 7,989

98.45 65

6

50-64

58

105 1

1 50

HIV

3. 10-15%

104 12 1

4.

5.

(1) 104 1 1 105 2 18 A

54

(2)104

(105)

1 15 272

()

1.104 105 2 18

43,685 22,765

19,968 418 19 534

228 74

2. 3

104 9

59

15

3

1

3.104 2,000 6

3 2

4.105 105

()

1. 71 104

71 A

6 2

B5 A16

2.

60

()

1.WEF2015

105 1 3

1,230 105 193

117 ( 60.6%)

15-24 54 28%

2.

104 5

11 19

3.104 834

417

386 92%

4.(

)

104

73

5.

6.

104 2 4

104 12 14

61

()

1. 104 5 25 WHO 2035

(105 109 )

2.10 33%

104

45.6 103(WEF) 69

3

3.(DOTS)104

10,491

96%

104 MDR 129

4. X

104

(IGRA) 7,037

(DOPT)

104 4,706

105 (LTBI)

62

5. 15 49

17%

94%(104 1 10 )

()

1.104

104

367

2.

7 104

45

10% 102 104

7 103 104

54 71

9%

14%

3.

104

63

188 131

21

4. 11

TB 22

11

5.104 12 30

()

1. 104 1(PCV)

2412 15

2.104-105 (NIIS)

()-MERS()

1.101

(MERS) 101

10 3

/

64

2.(WHO) 101 9 104 12

30 1,621 MERS584

5 20 12 24 186

38 WHO 12 24

98 MERS

3. 104 5

104 5 22

12 28

CDC 104 8 MERS

9

17

()

1.105 1 10 Zika

virus

2003

5

2. 105 1 22

2 2

24 /

/

65

(WHO)

2

1 WHO

2 2

2 18 12

3.

40 /

Alert

5 Watch

4.

()

104 1 12

66

60

1. 68

(Building resilient health systems)

6 28

2.104 APEC (HWG) 1

26-27

APEC Conference on revention,Control and

Care for Multi-Drug Resistant Tuberculosis (MDR-

TB),and Supply of Second-Line Anti- Tuberculosis

Drug HWG

3.104 APEC 8 30 31

(Building a resilient and

innovation health system)

()

1.

104

67

2.

104 68 WHA (5 18 26 )

54

3.104 1 12

104 1 12

/ 78 1,010

60

20

4.

(1) 1 MERS-CoV 104 5 26

(2)104 3 19

8

(3)104 5 5

16

10

104

68

11 30 270

()

1. 104 12

18 133

( 53 1,110

)

2.104 12 5

580( 31 86

3,918)

3.104 12

9 2

4 ( 59

21

26

)

4. 95

(TaiwanIHA) 104 2 10

(National Institute for

Emergency Medicine, NIEM)104

4 13

(USAID/OFDA) Ren Van Slate

104 5 TaiwanIHA

5 Futung

Bishnu Prd. Chapagin

69

TaiwanIHA 104 5 27 31

(Association of Medical Doctors of

Asia, AMDA)

RSUD

Andi Makkasau ParePare

29 TaiwanIHA 104 10 1 7

AMDA

(Bodhgaya)

150

5. 12

()

1.104 1 12

20

2.104 11 1 2

2015

Public Health GovernanceGlobal Health

Governance Governance to Reduce Health

Inequality

11 9

32 66

1,122

2005

70

2015/1/20~21 2015-

2015/3/16~17 20

2015/3/26~29

2015/4/17

-

2015/4/29~30 APEC

(APEC Conference on

Management and Related

Scientific Detection of Food

Additives in Foods)

2015/5/12~13 2015

2015/6/2~3

2015/6/3 2015

2015/6/17~18 2015 (2015

International Health Promotion

Conference)

2015/6/18~19 2015 IUHPE Executive Board

meeting in Taiwan

2015/7/28 APEC :

(APEC

Conference on Challenges of

Global Governance:

71

Economic Integration and

Healthcare Policy)

2015/7/31

2015/09/19~22 :

2015/10/26~27 2015

2015/11/1~2 2015

2015/11/18~20 2015 15

INHPF

2015/11/23~24

2015/12/9 2015

2015/12/17~18 2015

2015/12/18~19

()

1.

104 817

2.104 1,889

2,001

3.

72

104

41

(SCI)()

4.

104 14

e

()

1.104

6 692

485 207 PI

108

2.

(AML)

104 7 2

WHO 2016

88.7%(CEA)

(iFOBT) 12.9% 51.6%

()

1.

73

(ONIVYDE)

104 10 FDA

2.(ENO1)

104 9

3. DBPR108

104 6

3

4.(PM10)

(PM2.5) PM2.5

PM2.5

(36.5%) (30.5%)

(16.3%)

PM2.5

5.

2- 12

74

6.

104 10

()

1. 104 20

58

2.

104 3

3.(JTCM) 104

40 76% PubMed

4.

20 15

15 8

()

(www.mohw.gov.tw)0627

http://www.mohw.gov.tw)

75

()

REOC

()

7 1319

()

()

1. 105 1

31 1 5,168

4 4,454

7,478

3 2,900

2.:

104 11 27

12 31

-

76

()

1. 104 7 14 627

2.

2

325

(105)

2 19 481

19-22 ( 41.9%) 23-35 (

39.7%)()

72% 481

3. 104 7 20

1

()

1. 104 6 27 104 9 30

()

4.36

104 12 30

95

77

2. VPN

3. 104

4.

()

1.

line

2.

(1) 104 6 27 12 31

(2) 104 12 31

(Biobrane Pelnac Terudermis

78

Acticoat) 409.8

3.

104 7 3

59

659

4.

700,038 cm2 34

571,671 cm2; 104.12.24 128,367 cm

2

11()

0206

()

1. 2 6

2 14 2 109

13

313

2.()

(

)()

() 220

0206 23

79

23 2 13 8

74

78 2,780

()

1.( REMOC) 2 6

6 REMOC

REMOC

REMOC

REMOC

2. REMOC

(EMS) 2

14 6 560 7

34 509 9

51 ( 9 )

3. 2 6

REMOC (

) 2 14

192

()

1.

() 105 2 6

2.

80

2 14 391

661

3. 24

2 14 26

9

4.

/

()

1.

2.

()

0206

200

3.()

4.

81

()

5. 105 2 6 2

15 561 34 105 2

15 18 44 ( 4

40 16 20 4)

517 3,000

44

6. 3 1

1

82

()

1.

2.

3.

()

1.

2.

3.()

()

()

1.

2.

3.

83

()

1.

2. 106

3.

4.

()

()

1. 105 1,096

2.

3.

()

()

()

1.

84

2.

3.

4.

()

1. 105 2 1

2.

13

()

()

()

()()

85

()

1.

(1)

(2)

2.

3

()

1.

2.

COPD

()

1.

2.

()

1. 55 64

86

2.

3.

()

1.

2. CDC

(UCL Institute of Health

Equity)

3.

()

()

105

()

()

104

87

()

1.

2.

3.

4.

5.

6.

NGO

7.

()

1.

2.

http://www.mohw.gov.tw/CHT/DOMHAOH/DM1_P.aspx?f_list_no=189&fod_list_no=0&doc_no=48304

88

()

1.

2.

3.

()

1.

2.

3.

()

1.

2.

3.

89

()

()

()

1.

2.

()

1.

2.

3.

()

90

1.

2.

3.

()

1.

2.//

3.

()

()

65

()

()

(GHSA)

MERS(

)

()

91

()(103-105 )

PI-initiated

()

()()

()

()

()(WHA)

()(WHO)

()(WHO)

()(APEC)(Health

Working GroupHWG)()

()

92

0206

/